A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
Paul G. Richardson(Harvard University), Kenneth C. Anderson(Dana-Farber Cancer Institute), Nikhil C. Munshi(Dana-Farber Cancer Institute), Deborah Doss(Dana-Farber Cancer Institute), Mohamed I. Zaki(Kuwait University), Rachid Baz(Moffitt Cancer Center), Susan L. Kelley(Multiple Myeloma Research Foundation), Melissa Alsina(Moffitt Cancer Center), Xin Yu(Shanghai Clinical Research Center), Daniel M. Sullivan(Moffitt Cancer Center), Laura McBride(Hackensack University Medical Center), David Siegel(Hackensack University Medical Center), Gail Larkins, Christian Jacques(Bibliothèque et Archives nationales du Québec), M. Lizza
Cited by 7
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k